BR112023022657A2 - Composições de vetor viral e métodos de uso das mesmas - Google Patents

Composições de vetor viral e métodos de uso das mesmas

Info

Publication number
BR112023022657A2
BR112023022657A2 BR112023022657A BR112023022657A BR112023022657A2 BR 112023022657 A2 BR112023022657 A2 BR 112023022657A2 BR 112023022657 A BR112023022657 A BR 112023022657A BR 112023022657 A BR112023022657 A BR 112023022657A BR 112023022657 A2 BR112023022657 A2 BR 112023022657A2
Authority
BR
Brazil
Prior art keywords
methods
viral vector
homology arms
compositions
vector compositions
Prior art date
Application number
BR112023022657A
Other languages
English (en)
Inventor
Nelson Chau B
Qiang Xiong
Original Assignee
Logicbio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Logicbio Therapeutics Inc filed Critical Logicbio Therapeutics Inc
Publication of BR112023022657A2 publication Critical patent/BR112023022657A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composições de vetor viral e métodos de uso das mesmas. composições e métodos para edição de genes melhorada com constructos de vetor aav são apresentados neste relatório. entre outras coisas, a presente divulgação reconhece que braços de homologia de um determinado comprimento (por exemplo, pelo menos 750 nt ou pelo menos 1000 nt cada) podem demonstrar atividade de edição melhorada. em algumas formas de realização, a presente divulgação reconhece que os braços de homologia de um determinado comprimento (por exemplo, pelo menos 750 nt ou pelo menos 1.000 nt cada) podem demonstrar melhorias adicionais na atividade de edição quando os braços de homologia têm comprimentos diferentes.
BR112023022657A 2021-04-30 2022-04-29 Composições de vetor viral e métodos de uso das mesmas BR112023022657A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182738P 2021-04-30 2021-04-30
PCT/US2022/026988 WO2022232545A1 (en) 2021-04-30 2022-04-29 Viral vector compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112023022657A2 true BR112023022657A2 (pt) 2024-01-16

Family

ID=83847345

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022657A BR112023022657A2 (pt) 2021-04-30 2022-04-29 Composições de vetor viral e métodos de uso das mesmas

Country Status (10)

Country Link
EP (1) EP4330417A1 (pt)
JP (1) JP2024517743A (pt)
KR (1) KR20240004566A (pt)
CN (1) CN117321215A (pt)
AU (1) AU2022264585A1 (pt)
BR (1) BR112023022657A2 (pt)
CA (1) CA3216909A1 (pt)
CO (1) CO2023015532A2 (pt)
TW (1) TW202309277A (pt)
WO (1) WO2022232545A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508463A (ja) * 2021-02-26 2024-02-27 ロジックバイオ セラピューティクス， インコーポレイテッド 組換えａａｖベクターの製造及び使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527435A (en) * 1998-05-15 2005-01-28 Stanford Res Inst Int Transgenic animals produced by homologous sequence targeting
CN106460009A (zh) * 2014-03-21 2017-02-22 小利兰·斯坦福大学托管委员会 无核酸酶的基因组编辑
JP2021520211A (ja) * 2018-04-05 2021-08-19 ジュノー セラピューティクス インコーポレイテッド 組換え受容体を発現するｔ細胞、関連ポリヌクレオチド、および方法
US20220218843A1 (en) * 2018-08-10 2022-07-14 Logicbio Therapeutics, Inc. Non-disruptive gene therapy for the treatment of mma

Also Published As

Publication number Publication date
CN117321215A (zh) 2023-12-29
JP2024517743A (ja) 2024-04-23
CA3216909A1 (en) 2022-11-03
KR20240004566A (ko) 2024-01-11
EP4330417A1 (en) 2024-03-06
CO2023015532A2 (es) 2023-11-30
AU2022264585A1 (en) 2023-11-30
TW202309277A (zh) 2023-03-01
WO2022232545A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
BR112022009895A2 (pt) Construtos de terapia de gene de microdistrofina e usos dos mesmos
MX2020004578A (es) Composiciones de casz y metodos de uso.
BR112019001887A2 (pt) composições e métodos para o tratamento de doença associada a cep290
CO2021006362A2 (es) Construcciones de ácido nucleico y métodos de uso
MX2020013357A (es) Polimerasas, composiciones y metodos de uso.
BR112018011193A2 (pt) métodos escalonáveis para produzir vetor viral adeno-associado (aav) recombinante em sistema de cultura celular em suspensão isento de soro adequado para uso clínico
CL2021002739A1 (es) Proteína crispr de prevotella y francisella 1 (cpf1) aislada de acidaminococcus sp. bv3l6; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
CL2021001973A1 (es) Compuesto heterocíclico y su uso.
BR112019006388A2 (pt) enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas
BR112023022657A2 (pt) Composições de vetor viral e métodos de uso das mesmas
BR112018010635A2 (pt) linhagens celulares estáveis para a produção retroviral
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
BR112021019436A2 (pt) Vetores de vírus adeno-associados (aav) modificados para expressão transgênica
BR112022002819A2 (pt) Polipeptídeos de interleucina 2 (il-2) modificados, conjugados e usos dos mesmos
CL2022002379A1 (es) Molécula de ácido nucleico interferente corto (sina); composición que la comprende; y su uso.
CO6190565A2 (es) Aptameros, metodos para su seleccion y usos
BR112021024978A2 (pt) Composições engajadoras específicas para macrófagos e métodos de uso das mesmas
BR112022009864A2 (pt) Variantes do vetor viral adenoassociado
CL2023001284A1 (es) Composiciones y métodos para el reemplazo de alelos con adn codificado por arn
BR112021012240A2 (pt) Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich
BR112022006476A2 (pt) Oligonucleotídeos com análogos de nucleosídeos
BR112017022578A2 (pt) agentes nucleosídicos para a redução da atividade deletéria de genes que contém repetições estendidas de nucleotídeos
BR112022005963A2 (pt) Células com expressão de transgenes sustentada
AR110908A1 (es) Constructo promotor para la síntesis de proteínas libre de células
AR107261A1 (es) Vacuna marcadora de pestivirus